"Phthalazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.
| Descriptor ID |
D010793
|
| MeSH Number(s) |
D03.383.710.605
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phthalazines".
Below are MeSH descriptors whose meaning is more specific than "Phthalazines".
This graph shows the total number of publications written about "Phthalazines" by people in this website by year, and whether "Phthalazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 4 | 1 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phthalazines" by people in Profiles.
-
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer. 2023 05 01; 129(9):1411-1418.
-
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 02; 7:e2200505.
-
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
-
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939.
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). J Clin Oncol. 2023 01 01; 41(1):43-53.
-
The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nat Commun. 2022 01 17; 13(1):187.
-
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
-
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clin Lung Cancer. 2021 09; 22(5):e703-e707.
-
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 20; 38(36):4274-4282.
-
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968.